1
|
Keij FM, Kornelisse RF, Hartwig NG, van der Sluijs-Bens J, van Beek RHT, van Driel A, van Rooij LGM, van Dalen-Vink I, Driessen GJA, Kenter S, von Lindern JS, Eijkemans M, Stam-Stigter GM, Qi H, van den Berg MM, Baartmans MGA, van der Meer-Kappelle LH, Meijssen CB, Norbruis OF, Heidema J, van Rossem MC, den Butter PCP, Allegaert K, Reiss IKM, Tramper-Stranders GA. Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial. Lancet Child Adolesc Health 2022; 6:799-809. [PMID: 36088952 DOI: 10.1016/s2352-4642(22)00245-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Revised: 07/25/2022] [Accepted: 08/09/2022] [Indexed: 10/14/2022]
Abstract
BACKGROUND Switching from intravenous antibiotic therapy to oral antibiotic therapy among neonates is not yet practised in high-income settings due to uncertainties about exposure and safety. We aimed to assess the efficacy and safety of early intravenous-to-oral antibiotic switch therapy compared with a full course of intravenous antibiotics among neonates with probable bacterial infection. METHODS In this multicentre, randomised, open-label, non-inferiority trial, patients were recruited at 17 hospitals in the Netherlands. Neonates (postmenstrual age ≥35 weeks, postnatal age 0-28 days, bodyweight ≥2 kg) in whom prolonged antibiotic treatment was indicated because of a probable bacterial infection, were randomly assigned (1:1) to switch to an oral suspension of amoxicillin 75 mg/kg plus clavulanic acid 18·75 mg/kg (in a 4:1 dosing ratio, given daily in three doses) or continue on intravenous antibiotics (according to the local protocol). Both groups were treated for 7 days. The primary outcome was cumulative bacterial reinfection rate 28 days after treatment completion. A margin of 3% was deemed to indicate non-inferiority, thus if the reinfection rate in the oral amoxicillin-clavulanic acid group was less than 3% higher than that in the intravenous antibiotic group the null hypothesis would be rejected. The primary outcome was assessed in the intention-to-treat population (ie, all patients who were randomly assigned and completed the final follow-up visit on day 35) and the per protocol population. Safety was analysed in all patients who received at least one administration of the allocated treatment and who completed at least one follow-up visit. Secondary outcomes included clinical deterioration and duration of hospitalisation. This trial was registered with ClinicalTrials.gov, NCT03247920, and EudraCT, 2016-004447-36. FINDINGS Between Feb 8, 2018 and May 12, 2021, 510 neonates were randomly assigned (n=255 oral amoxicillin-clavulanic group; n=255 intravenous antibiotic group). After excluding those who withdrew consent (n=4), did not fulfil inclusion criteria (n=1), and lost to follow-up (n=1), 252 neonates in each group were included in the intention-to-treat population. The cumulative reinfection rate at day 28 was similar between groups (one [<1%] of 252 neonates in the amoxicillin-clavulanic acid group vs one [<1%] of 252 neonates in the intravenous antibiotics group; between-group difference 0 [95% CI -1·9 to 1·9]; pnon-inferiority<0·0001). No statistically significant differences were observed in reported adverse events (127 [50%] vs 113 [45%]; p=0·247). In the intention-to-treat population, median duration of hospitalisation was significantly shorter in the amoxicillin-clavulanic acid group than the intravenous antibiotics group (3·4 days [95% CI 3·0-4·1] vs 6·8 days [6·5-7·0]; p<0·0001). INTERPRETATION An early intravenous-to-oral antibiotic switch with amoxicillin-clavulanic acid is non-inferior to a full course of intravenous antibiotics in neonates with probable bacterial infection and is not associated with an increased incidence of adverse events. FUNDING The Netherlands Organization for Health Research and Development, Innovatiefonds Zorgverzekeraars, and the Sophia Foundation for Scientific Research.
Collapse
Affiliation(s)
- Fleur M Keij
- Department of Paediatrics, Division of Neonatology, Erasmus University Medical Centre-Sophia Children's Hospital, Rotterdam, Netherlands; Department of Paediatrics, Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands.
| | - René F Kornelisse
- Department of Paediatrics, Division of Neonatology, Erasmus University Medical Centre-Sophia Children's Hospital, Rotterdam, Netherlands
| | - Nico G Hartwig
- Department of Paediatrics, Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands
| | | | | | - Arianne van Driel
- Department of Paediatrics, IJsselland Hospital, Capelle aan den IJssel, Netherlands
| | | | - Ilka van Dalen-Vink
- Department of Paediatrics, Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands
| | - Gertjan J A Driessen
- Department of Paediatrics, Juliana Children's Hospital, Haga Teaching Hospital, the Hague, Netherlands
| | - Sandra Kenter
- Department of Paediatrics, Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands
| | | | | | | | - Hongchao Qi
- Department of Biostatistics, Erasmus University Medical Centre, Rotterdam, Netherlands
| | | | | | | | - Clemens B Meijssen
- Department of Paediatrics, Meander Medical Centre, Amersfoort, Netherlands
| | - Obbe F Norbruis
- Department of Paediatrics, Isala Hospital, Zwolle, Netherlands
| | - Jojanneke Heidema
- Department of Paediatrics, St Antonius Hospital, Nieuwegein, Netherlands
| | | | | | - Karel Allegaert
- Department of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, Netherlands; Department of Development and Regeneration and Department of Pharmaceutical and Pharmacological Sciences, Catholic University of Leuven, Leuven, Belgium
| | - Irwin K M Reiss
- Department of Paediatrics, Division of Neonatology, Erasmus University Medical Centre-Sophia Children's Hospital, Rotterdam, Netherlands
| | - Gerdien A Tramper-Stranders
- Department of Paediatrics, Division of Neonatology, Erasmus University Medical Centre-Sophia Children's Hospital, Rotterdam, Netherlands; Department of Paediatrics, Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands.
| |
Collapse
|
2
|
van Dongen JAP, Rouers EDM, Schuurman R, Band C, Watkins SM, van Houten MA, Bont LJ, Norbruis OF, Hemels MAC, van Well GTJ, Vlieger AM, van der Sluijs J, Stas HG, Tramper-Stranders G, Kleinlugtenbeld EA, van Kempen AAMW, Wessels M, van Rossem MC, Dassel CACM, Pajkrt D, Bonten MJM, Bruijning-Verhagen PCJ. Rotavirus Vaccine Safety and Effectiveness in Infants With High-Risk Medical Conditions. Pediatrics 2021; 148:183442. [PMID: 34814164 DOI: 10.1542/peds.2021-051901] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 09/21/2021] [Indexed: 11/24/2022] Open
Abstract
OBJECTIVES Rotavirus vaccination has 87% to 100% effectiveness against severe rotavirus acute gastroenteritis (AGE) in healthy infants in high-income countries. Little is known whether infants with medical risk conditions (MRCs) are equally protected and if the vaccine is equally well tolerated. We conducted a quasi-experimental prospective multicenter before-after cohort study to assess the vaccine effectiveness (VE) and safety profile of the human rotavirus vaccine (HRV) among MRC infants that required prolonged or frequent postnatal care. METHODS The Netherlands has no national rotavirus immunization program, but HRV was implemented in routine care for MRC infants in 13 Dutch hospitals. Participants in the before and after cohort, HRV unvaccinated and vaccinated, respectively, were followed for occurrence of (rotavirus) AGE. VE of at least 1 dose was estimated by using time-to-event analysis for severe rotavirus AGE. Vaccine-related serious adverse event (AEs) after HRV were retrieved systematically from medical charts. Solicited AEs after vaccinations were prospectively collected and compared between vaccination time points with or without HRV. RESULTS In total, 1482 high-risk infants with MRC were enrolled, including 631 in the before and 851 in the after cohorts; 1302 infants were premature (88.3%), 447 were small for gestational age (30.2%), and 251 had at least 1 congenital disorder (17.0%). VE against severe rotavirus AGE was 30% (95% confidence interval [CI]: -36% to 65%). Overall, the observed number of rotavirus hospitalizations was low and not significantly different between the cohorts (2 and 2, respectively). The rate of vaccine-related serious AE was 0.24 per 100 vaccine doses. The adjusted risk ratio for any AE after HRV vaccination compared with other routine vaccinations was 1.09 (95% CI: 1.05 to 1.12) for concomitant administration and 0.91 (95% CI: 0.81 to 0.99) for single HRV administration. Gastrointestinal AEs were 10% more frequent after HRV. CONCLUSIONS In contrast to previous findings among healthy term infants, in routine use, HRV offered limited protection to vulnerable medical risk infants. HRV is generally well tolerated in this group in single administration, but when coadministered with routine vaccines, it is associated with higher risk of (mostly gastrointestinal) AE. Our study highlights the importance of studying vaccine performance in subgroups of medically vulnerable infants.
Collapse
Affiliation(s)
| | - Elsbeth D M Rouers
- Julius Center for Health Sciences and Primary Care, Epidemiology of Infectious Diseases.,National Institute for Public Health and the Environment, Center for Infectious Disease Control, Bilthoven, Netherlands
| | | | - Caterina Band
- Department of Pediatrics, Spaarne Gasthuis, Haarlem and Hoofddorp, Netherlands
| | - Shannon M Watkins
- Julius Center for Health Sciences and Primary Care, Epidemiology of Infectious Diseases
| | | | - Louis J Bont
- Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands
| | - Obbe F Norbruis
- Department of Pediatrics, Isala Hospital, Zwolle, Netherlands
| | | | - Gijs T J van Well
- Department of Pediatrics, Maastricht University Medical Centre, Maastricht, Netherlands
| | - Arine M Vlieger
- Department of Pediatrics, St Antonius Hospital, Nieuwegein, Netherlands
| | | | - Helene G Stas
- Department of Pediatrics, Maasstad Hospital, Rotterdam, Netherlands
| | | | | | | | - Margreet Wessels
- Department of Pediatrics, Rijnstate Hospital, Arnhem, Netherlands
| | | | | | - Dasja Pajkrt
- Department of Pediatrics, Amsterdam University Medical Centre, Amsterdam, Netherlands
| | - Marc J M Bonten
- Julius Center for Health Sciences and Primary Care, Epidemiology of Infectious Diseases.,Departments of Medical Microbiology.,National Institute for Public Health and the Environment, Center for Infectious Disease Control, Bilthoven, Netherlands
| | - Patricia C J Bruijning-Verhagen
- Julius Center for Health Sciences and Primary Care, Epidemiology of Infectious Diseases.,Departments of Medical Microbiology.,National Institute for Public Health and the Environment, Center for Infectious Disease Control, Bilthoven, Netherlands
| |
Collapse
|
3
|
van Rossem MC, van de Loo M, Laan BJ, de Sonnaville ESV, Tamminga P, van Kaam AH, Onland W. Accuracy of the Diagnosis of Bronchopulmonary Dysplasia in a Referral-Based Health Care System. J Pediatr 2015; 167:540-4.e1. [PMID: 26047684 DOI: 10.1016/j.jpeds.2015.05.008] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/15/2015] [Revised: 04/10/2015] [Accepted: 05/06/2015] [Indexed: 11/19/2022]
Abstract
OBJECTIVE To evaluate the accuracy of the diagnosis of bronchopulmonary dysplasia (BPD) in a national database of a referral-based health care system, where preterm infants are often transferred back to regional hospitals before 36 weeks postmenstrual age (PMA). STUDY DESIGN We evaluated preterm infants <32 weeks, born between 2004 and 2008 in the Academic Medical Center in Amsterdam with a high-risk profile for BPD. In addition to patient characteristics and outcomes, we collected data on respiratory support at 36 weeks PMA. True incidence of BPD, defined as needing supplemental oxygen and/or positive pressure support at 36 weeks PMA, was compared with the diagnosis registered in the National Perinatal Registry. Two imputation algorithms for patients transferred before 36 weeks PMA were validated. RESULTS We identified 243 preterm infants with a high-risk BPD profile. Sixty-seven percent of these infants had a correct BPD diagnosis recorded in the National Perinatal Registry, 2% had a false positive, and 31% a false negative diagnosis. Infants with a false negative diagnosis of BPD were twice as often transferred to a regional hospital before 36 weeks PMA compared with a true positive diagnosis. Imputation algorithms did not improve the accuracy of BPD registration. CONCLUSIONS Registration of the diagnosis BPD in a national database in countries with a referral-based health care system may not be accurate. Optimizing data collection and monitoring data entry is necessary to improve BPD registration before data can be used for national and international benchmarking.
Collapse
Affiliation(s)
- Maaike C van Rossem
- Department of Neonatology, Academic Medical Center, Emma Children's Hospital, Amsterdam, The Netherlands
| | - Moniek van de Loo
- Department of Neonatology, Academic Medical Center, Emma Children's Hospital, Amsterdam, The Netherlands
| | - Bart J Laan
- Department of Neonatology, Academic Medical Center, Emma Children's Hospital, Amsterdam, The Netherlands
| | - Eleonore S V de Sonnaville
- Department of Neonatology, Academic Medical Center, Emma Children's Hospital, Amsterdam, The Netherlands
| | - Pieter Tamminga
- Department of Neonatology, Academic Medical Center, Emma Children's Hospital, Amsterdam, The Netherlands
| | - Anton H van Kaam
- Department of Neonatology, Academic Medical Center, Emma Children's Hospital, Amsterdam, The Netherlands
| | - Wes Onland
- Department of Neonatology, Academic Medical Center, Emma Children's Hospital, Amsterdam, The Netherlands.
| |
Collapse
|